Related content

Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens

By                    

Oncology Letters, Vol. 2, Iss. 2, 2011-01 ,pp. : 247-251

Spandidos Publications

Access to resources Recommend Favorite

Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

By Kang Eun   Im Seock-Ah   Oh Do-Youn   Han Sae-Won   Kim Jin-Soo   Choi In   Kim Jin   Kim Yu   Kim Jee   Kim Tae-You   Lee Jong   Bang Yung-Jue   Lee Keun-Wook  

Gastric Cancer, Vol. 16, Iss. 4, 2013-10 ,pp. : 581-589

Springer Publishing Company

Access to resources Recommend Favorite

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

By Marcuello E.   Altés A.   Menoyo A.   Rio E.   Baiget M.  

Cancer Chemotherapy and Pharmacology, Vol. 57, Iss. 6, 2006-06 ,pp. : 835-840

Springer Publishing Company

Access to resources Recommend Favorite

Thymidylate Synthase and Dihydropyrimidine Dehydrogenase are Related to Histological Effects of 5-Fluorouracil and Cisplatin Neoadjuvant Chemotherapy for Primary Gastric Cancer Patients

By Fukuda Hiroyuki   Takiguchi Nobuhiro   Koda Kenji   Oda Kenji   Seike Kazuhiro   Miyazaki Masaru  

Cancer Investigation, Vol. 24, Iss. 3, 2006-05 ,pp. : 235-241

Informa Healthcare

Access to resources Recommend Favorite

Irinotecan, leucovorin and 5fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer

By                      

Oncology Letters, Vol. 4, Iss. 4, 2012-01 ,pp. : 751-754

Spandidos Publications

Access to resources Recommend Favorite